

MINUTES FROM THE EPA SCIENCE ADVISORY BOARD
Acrylamide Review Panel
Public Teleconference
July 16, 2008

PURPOSE: The Acrylamide Review Panel of the EPA Science Advisory Board (SAB) met on July 16, 2008 via teleconference. The purpose of this teleconference was to offer an opportunity for panel members to discuss their draft report concerning the Agency's draft IRIS review entitled, *Toxicological Review of Acrylamide*. There was an opportunity for panel members to refine their responses to the charge questions. The SAB Acrylamide Review Panel had been asked to comment on the scientific soundness of EPA's IRIS assessment. Attachment A is the Federal Register notice announcing the meetings (73 FR 123:3675-3676 June 25, 2008). A meeting agenda is included as Attachment B.

LOCATION: By telephone only.

DATE AND TIME: July 16, 2008 from 1:00 – 4:00 PM Eastern Time.

PARTICIPANTS: The following individuals participated in this meeting: SAB Committee and Board Members - Drs. Deborah Cory-Slechta (Chair), Alfred Branen, Daniel Doerge, James Felton, Timothy Fennell, Penelope Fenner-Crisp, Jeffery Fisher, Sean Hays, Steven Heeringa, Richard LopPachin, Lorelei Mucci, Jerry M. Rice, Dale Sickles, Gina Solomon, Anne Swenney, Lauren Zeise. The Review Panel roster is included as Attachment C and a set of biographical sketches is included in Attachment D. SAB Staff - Dr. Sue Shallal, Designated Federal Officers (DFO); EPA Representatives – Rob Dewoskin, Ila Cote and John Vandenberg. Other Participants – Other EPA staff and members of the public listened in to the discussions. A list of the names of individuals who registered to listen-in is attached (Attachment E).

MEETING SUMMARY: The meeting followed the agenda (Attachment B). A summary of the meeting follows.

Final MINUTES

Convene the Meeting and Introductory Remarks – Dr. Suhair Shallal, Designated Federal Officer (DFO), opened the meeting at 1:05 PM after allowing time for panel members to dial in to the teleconference. She called roll and determined that all panel members were present. She reminded the audience that the panel has met previously on two occasions. She presented background information on the SAB panel formation process and informed the audience that the SAB operates under the rules and regulations of FACA where all meetings, during which discussions and deliberations take place, are held in public. She also reminded the members of the panel and the audience that the draft panel report including the charge questions (Attachment F) can be found on the SAB website.

Welcome - Dr. Cory-Slechta then reviewed the agenda and explained the purpose of the teleconference. She stated that the meeting would begin with presentations from registered public commenters and the panel members will be able to ask clarifying questions.

Public Comments

Dr. Jerry Hardisty had registered but he was not available.

Dr. Robert Maronpot, a Board certified toxicologist and pathologist had worked at the NTP for a number of years. He discussed the tumor response associated with exposure to Acrylamide, specifically Tunica Vaginalis Mesothelioma. He explained his view that this tumor appears as a result of a non-mutagenic MOA in the case of exposure to Acrylamide.

Dr. Gene McConnell had registered but was not available.

Dr. Annette Shipp then presented her comments which focused on the use of the Human Relevance Framework (HRF) for assessing Acrylamide effects.

Dr. Marvin Freidman presented his comments concerning the carcinogenicity of acrylamide and the plausibility of non-mutagenic MOAs.

Dr. Michael Dourson then presented his comments. He talked about his research on the tumorigenicity of acrylamide. He presented evidence for a non-mutagenic MOA and suggested that more than one quantitative analysis should be done, both for a mutagenic and a non-mutagenic MOA.

All public comments including those provided by the commenters listed above can be found at the following URL:

Final MINUTES

<http://yosemite.epa.gov/sab/sabproduct.nsf/MeetingCal/CA6FD5BAAAE27D1285257465005226D3?OpenDocument>

Dr. Cory-Slechta thanked the public commenters.

Discussion of the report

Dr. Cory-Slechta stated that the discussion of the report would occur question by question. An in-depth discussion of each charge question ensued. There were a number of minor modifications that were suggested throughout the body of the report. Major areas of discussion included:

- The debate concerning the classification of malignant reticulosis as tumors of glial origin and their inclusion in the analysis. The panel agreed with the Agency's approach, concluding that their removal was not justified since not enough information was available to warrant disregarding them.
- Further refinement of the response to Charge Question 8 was suggested. New text was added that had not had been fully evaluated and therefore, several members agreed to review the references that had been submitted and to revise the text accordingly.
- Finally, Charge Question 20 was also found to require major revisions and several panel members agreed to provide appropriate changes.

Dr. Cory Slechta then asked members if they had comments on the Executive Summary, as well as, the letter to the Administrator. A few minor changes were suggested to each. Members suggested that the Executive Summary and the letter be modified to reflect the changes that had been suggested in the body of the report.

After completing the discussion of the report, Dr. Cory-Slechta asked if Agency representatives had any comments. In response, Dr. Rob Dewoskin made some remarks thanking the panel for the review of the Agency's draft document. He informed the panel that the Agency intends to incorporate more recent data and revise the model before finalizing their document.

Dr. Cory-Slechta then thanked the panel members for a very productive meeting and a very informative review. She then asked Dr. Shallal to make her concluding remarks.

Final MINUTES

Dr. Shallal reminded panel members to include her as a recipient on any correspondence with other panel members and to send their revisions by July 30, 2008. She also explained the process for finalizing the Panel's report stating that the report will remain draft until it has been approved by the chartered SAB.

The meeting adjourned at approximately 4:20 PM.

Respectfully Submitted:

Dr. Suhair Shallal

Designated Federal Officer, EPA SAB Acrylamide Review Panel

I certify that these minutes are accurate to the best of my knowledge:

Dr. Deborah Cory-Slechta

Chair, EPA SAB Acrylamide Review Panel

Final MINUTES

All attachments are available in hardcopy upon request

<u>Attachment A</u>	Federal Register notice (73 FR 123:3675-3676 June 25, 2008)
<u>Attachment B</u>	Meeting agenda- July 16, 2008
<u>Attachment C</u>	Consultative Panel roster
<u>Attachment D</u>	Biographical sketches
<u>Attachment E</u>	List of participants
<u>Attachment F</u>	Charge Questions